Focus: InMed Pharmaceuticals is a public biotech company focused on cannabinoid-based therapeutics, leveraging proprietary cannabinoid research and database capabilities. The company operates at a small scale with a lean pipeline concentrated in neurology.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow InMed Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from InMed Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Help build intelligence for InMed Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
InMed Pharmaceuticals (INM) Edges Higher: Shares Gain 1.10% to $1.38 - Trend Continuation Trade - siam.in
InMed Pharmaceuticals (INM) Edges Higher: Shares Gain 1.10% to $1.38 - Trend Continuation Trade siam.in
InMed Faces Nasdaq Equity Shortfall but Banks on Mentari Merger to Regain Compliance - The Globe and Mail
InMed Faces Nasdaq Equity Shortfall but Banks on Mentari Merger to Regain Compliance The Globe and Mail
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance - TMX Newsfile
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance TMX Newsfile
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance - Yahoo! Finance Canada
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance Yahoo! Finance Canada
Nasdaq gives InMed 45 days to submit a compliance plan - Stock Titan
Nasdaq gives InMed 45 days to submit a compliance plan Stock Titan
InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update - TMX Newsfile
InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update TMX Newsfile
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications